TECENTRIQ (Genentech, Inc.)
Welcome to the PulseAid listing for the TECENTRIQ drug offered from Genentech, Inc.. This Programmed Death Receptor-1 Blocking Antibody [EPC],Programmed Death Receptor-1-directed Antibody Interactions [MoA],Antibodies, Monoclonal, Humanized [Chemical/Ingredient],Antibodies, Monoclonal [Chemical/Ingredient],Antibodies [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Genentech, Inc. |
| NON-PROPRIETARY NAME: | atezolizumab |
| SUBSTANCE NAME: | ATEZOLIZUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Programmed Death Receptor-1 Blocking Antibody [EPC],Programmed Death Receptor-1-directed Antibody Interactions [MoA],Antibodies, Monoclonal, Humanized [Chemical/Ingredient],Antibodies, Monoclonal [Chemical/Ingredient],Antibodies [Chemical/Ingredient] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2016-05-18 |
| END MARKETING DATE: | 0000-00-00 |
TECENTRIQ HUMAN PRESCRIPTION DRUG Details:
| Item Description | TECENTRIQ from Genentech, Inc. |
| LABELER NAME: | Genentech, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 1200(mg/20mL) |
| START MARKETING DATE: | 2016-05-18 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 50242-917_04707e26-3472-42d0-becf-2a05f73b5112 |
| PRODUCT NDC: | 50242-917 |
| APPLICATION NUMBER: | BLA761034 |
Other ATEZOLIZUMAB Pharmaceutical Manufacturers / Labelers:
